2024
Salvage lung resection after immunotherapy is feasible and safe
Nemeth A, Canavan M, Zhan P, Udelsman B, Ely S, Wigle D, Martin L, Yang C, Boffa D, Dhanasopon A. Salvage lung resection after immunotherapy is feasible and safe. JTCVS Open 2024, 20: 141-150. PMID: 39296459, PMCID: PMC11405986, DOI: 10.1016/j.xjon.2024.03.018.Peer-Reviewed Original ResearchNon-small cell lung cancerComplete pathologic responseSalvage lung resectionNational Cancer DatabaseLength of stayStages I-IVLung resectionOligo-progressionOverall survivalSalvage surgeryComplete resection (R0Comprehensive multidisciplinary treatment planHigher R0 resection rateCohort study of patientsInitiation of immunotherapyR0 resection rateTreated with immunotherapySalvage treatment optionMortality rateCell lung cancerLow patient morbidityMedian length of stayKaplan-Meier analysisMultidisciplinary treatment planStudy of patients
2021
Optimal Radiation Dose for Stage III Lung Cancer—Should “Definitive” Radiation Doses Be Used in the Preoperative Setting?
Saffarzadeh AG, Canavan M, Resio BJ, Walters SL, Flores KM, Decker RH, Boffa DJ. Optimal Radiation Dose for Stage III Lung Cancer—Should “Definitive” Radiation Doses Be Used in the Preoperative Setting? JTO Clinical And Research Reports 2021, 2: 100201. PMID: 34590044, PMCID: PMC8474436, DOI: 10.1016/j.jtocrr.2021.100201.Peer-Reviewed Original ResearchLong-term mortality riskStage III NSCLCLow dosePreoperative settingMortality riskHigh doseRadiation doseClinical stage III patientsNational Cancer Database dataStage III lung cancerStage III patientsUse of surgeryLength of stayGy of radiationCox proportional hazardsComparative effectiveness analysisOptimal radiation doseSingle-dose strategyLong-term survivalRadiation dosesLogistic regression modelsDefinitive chemoradiotherapyN2 patientsNonsurgical patientsPerioperative outcomes